Literature DB >> 27449499

The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.

Kun Guo1,2, Jiujie Cui2, Ming Quan2,3, Dacheng Xie3, Zhiliang Jia2, Daoyan Wei2, Liang Wang2, Yong Gao4, Qingyong Ma5, Keping Xie6.   

Abstract

PURPOSE: Musashi 2 (MSI2) is reported to be a potential oncoprotein in cases of leukemia and several solid tumors. However, its expression, function, and regulation in pancreatic ductal adenocarcinoma (PDAC) cases have yet to be demonstrated. Therefore, in the current study, we investigated the clinical significance and biologic effects of MSI2 expression in PDAC cases and sought to delineate the clinical significance of the newly identified Krüppel-like factor 4 (KLF4)/MSI2 regulatory pathway. EXPERIMENTAL
DESIGN: MSI2 expression and its association with multiple clinicopathologic characteristics in human PDAC specimens were analyzed immunohistochemically. The biological functions of MSI2 regarding PDAC cell growth, migration, invasion, and metastasis were studied using gain- and loss-of-function assays both in vitro and in vivo Regulation of MSI2 expression by KLF4 was examined in several cancer cell lines, and the underlying mechanisms were studied using molecular biologic methods.
RESULTS: MSI2 expression was markedly increased in both PDAC cell lines and human PDAC specimens, and high MSI2 expression was associated with poor prognosis for PDAC. Forced MSI2 expression promoted PDAC proliferation, migration, and invasion in vitro and growth and metastasis in vivo, whereas knockdown of MSI2 expression did the opposite. Transcriptional inhibition of MSI2 expression by KLF4 occurred in multiple PDAC cell lines as well as mouse models of PDAC.
CONCLUSIONS: Lost expression of KLF4, a transcriptional repressor of MSI2 results in overexpression of MSI2 in PDACs, which may be a biomarker for accurate prognosis. A dysregulated KLF4/MSI2 signaling pathway promotes PDAC progression and metastasis. Clin Cancer Res; 23(3); 687-96. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27449499      PMCID: PMC5253336          DOI: 10.1158/1078-0432.CCR-16-1064

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity.

Authors:  Kristin J Hope; Sonia Cellot; Stephen B Ting; Tara MacRae; Nadine Mayotte; Norman N Iscove; Guy Sauvageau
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

2.  Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.

Authors:  Lei Li; Zhaoshen Li; Xiangyu Kong; Dacheng Xie; Zhiliang Jia; Weihua Jiang; Jiujie Cui; Yiqi Du; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Gastroenterology       Date:  2014-05-20       Impact factor: 22.682

3.  Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway.

Authors:  Ming-Hai Wang; Shi-Yong Qin; Shu-Guang Zhang; Guang-Xin Li; Zhen-Hai Yu; Kun Wang; Bin Wang; Mu-Jian Teng; Zhi-Hai Peng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis.

Authors:  Jianfei Xue; Xia Lin; Wen-Tai Chiu; Yao-Hui Chen; Guanzhen Yu; Mingguang Liu; Xin-Hua Feng; Raymond Sawaya; René H Medema; Mien-Chie Hung; Suyun Huang
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  Identification and characterization of a gene encoding a gut-enriched Krüppel-like factor expressed during growth arrest.

Authors:  J M Shields; R J Christy; V W Yang
Journal:  J Biol Chem       Date:  1996-08-16       Impact factor: 5.157

Review 6.  Musashi 2 in hematopoiesis.

Authors:  Luisa de Andrés-Aguayo; Florencio Varas; Thomas Graf
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

7.  A gene for a novel zinc-finger protein expressed in differentiated epithelial cells and transiently in certain mesenchymal cells.

Authors:  L A Garrett-Sinha; H Eberspaecher; M F Seldin; B de Crombrugghe
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

8.  Liver metastases are enhanced in homozygous deletionally mutant ICAM-1 or LFA-1 mice.

Authors:  M R Marvin; J C Southall; S Trokhan; C DeRosa; J Chabot
Journal:  J Surg Res       Date:  1998-12       Impact factor: 2.192

9.  A novel TTC40-MSI2 fusion in de novo acute myeloid leukemia with an unbalanced 10;17 translocation.

Authors:  Reza Saleki; Todd Christensen; Weihua Liu; Xiaowen Wang; Qing C Chen; Matthew Aakre; Nuno M V Gomes; Borislav A Alexiev; Joseph Schappert; Maria R Baer; Ying S Zou
Journal:  Leuk Lymphoma       Date:  2014-08-20

10.  The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells.

Authors:  Parvaneh Nikpour; Modjtaba Emadi Baygi; Christine Steinhoff; Christiane Hader; Anna C Luca; Seyed J Mowla; Wolfgang A Schulz
Journal:  J Cell Mol Med       Date:  2010-05-14       Impact factor: 5.310

View more
  33 in total

Review 1.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

Authors:  Alexander E Kudinov; John Karanicolas; Erica A Golemis; Yanis Boumber
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

2.  ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.

Authors:  Tiansuo Zhao; Wenna Jiang; Xiuchao Wang; Hongwei Wang; Chen Zheng; Yang Li; Yan Sun; Chongbiao Huang; Zhi-Bo Han; Shengyu Yang; Zhiliang Jia; Keping Xie; He Ren; Jihui Hao
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

3.  Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial-Mesenchymal Transition.

Authors:  Fanyang Kong; Tao Sun; Xiangyu Kong; Dacheng Xie; Zhaoshen Li; Keping Xie
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

4.  Five gene signatures were identified in the prediction of overall survival in resectable pancreatic cancer.

Authors:  Chao Wu; Zuowei Wu; Bole Tian
Journal:  BMC Surg       Date:  2020-09-17       Impact factor: 2.102

5.  CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer.

Authors:  Chuan Liu; Xiaowei Fu; Zhiwei Zhong; Jing Zhang; Haiyan Mou; Qiong Wu; Tianle Sheng; Bo Huang; Yeqing Zou
Journal:  Dig Dis Sci       Date:  2017-06-23       Impact factor: 3.199

Review 6.  [Advances in research of Musashi2 in solid tumors].

Authors:  Y Yang; M Zhao; T Ding; C Ni; Q Zheng; X Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-03-20

Review 7.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

8.  Human oncoprotein Musashi-2 N-terminal RNA recognition motif backbone assignment and identification of RNA-binding pocket.

Authors:  Lan Lan; Minli Xing; Justin T Douglas; Philip Gao; Robert P Hanzlik; Liang Xu
Journal:  Oncotarget       Date:  2017-11-20

Review 9.  The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.

Authors:  Shun Wang; Yan Zheng; Feng Yang; Le Zhu; Xiao-Qiang Zhu; Zhe-Fang Wang; Xiao-Lin Wu; Cheng-Hui Zhou; Jia-Yan Yan; Bei-Yuan Hu; Bo Kong; De-Liang Fu; Christiane Bruns; Yue Zhao; Lun-Xiu Qin; Qiong-Zhu Dong
Journal:  Signal Transduct Target Ther       Date:  2021-07-05

10.  Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression.

Authors:  Leonid Kharin; Igor Bychkov; Nikolay Karnaukhov; Mark Voloshin; Rushaniya Fazliyeva; Alexander Deneka; Elena Frantsiyants; Oleg Kit; Erica Golemis; Yanis Boumber
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.